chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Dizziness, Dysphonia, Head discomfort, Interchange of vaccine products
Clinical narrative: My first 3 doses were Moderna and my 4th dose was Pfizer. Starting 05/11/2022, I had a sore throat, hoarseness, sinus congestion, chest congestion and fever. The fever went away and then I was tested and it was positive for COVID. So, I did a telehealth visit with my doctor and she prescribed Paxlovid. I felt really good for 2 days and now I am having head congestion again and some slight dizziness.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Oropharyngeal pain, Pyrexia, Respiratory tract congestion, SARS-CoV-2 test positive, Sinus congestion
Clinical narrative: My first 3 doses were Moderna and my 4th dose was Pfizer. Starting 05/11/2022, I had a sore throat, hoarseness, sinus congestion, chest congestion and fever. The fever went away and then I was tested and it was positive for COVID. So, I did a telehealth visit with my doctor and she prescribed Paxlovid. I felt really good for 2 days and now I am having head congestion again and some slight dizziness.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Oedema, Pruritus
Clinical narrative: On 05/08/22 developed intense pruritus at fingertips and DIP joints, progressing to palmar aspect of hands at joints; then periorbital, perioral itching, minimal edema; progressed then to forehead and upper arms/deltoids (B) pruritus. Patient has self-administered oral diphenhydramine 25mg TID and topical hydrocortisone 0.1% for some relief. Seen in clinic 05/19/22 and continued pruritus treated with methylprednisolone 4mg tablet taper (12mg x4days, 8mg x4days, 4mg x4days).
Age: 48.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Antinuclear antibody, Arthralgia, Biopsy thyroid gland, C-reactive protein, Depression
Clinical narrative: Profound fatigue, muscle aches and pains throughout body, joint aches, headaches, brain fog, lymph node swelling throughout body, insomnia, depression
Age: 48.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Differential white blood cell count, Electrocardiogram, Fatigue, Feeling abnormal, Full blood count
Clinical narrative: Profound fatigue, muscle aches and pains throughout body, joint aches, headaches, brain fog, lymph node swelling throughout body, insomnia, depression
Age: 48.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Headache, Insomnia, Laboratory test, Lymphadenopathy, Mammogram
Clinical narrative: Profound fatigue, muscle aches and pains throughout body, joint aches, headaches, brain fog, lymph node swelling throughout body, insomnia, depression
Age: 48.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Metabolic function test, Myalgia, Red blood cell sedimentation rate, Ultrasound abdomen, Ultrasound scan
Clinical narrative: Profound fatigue, muscle aches and pains throughout body, joint aches, headaches, brain fog, lymph node swelling throughout body, insomnia, depression
Age: 48.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Urine analysis
Clinical narrative: Profound fatigue, muscle aches and pains throughout body, joint aches, headaches, brain fog, lymph node swelling throughout body, insomnia, depression
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 72.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Angiogram cerebral normal, COVID-19, Carotid arteriosclerosis, Carotid artery stenosis, Cerebral atrophy
Clinical narrative: Hospitalized 05/15/2022-05/19/2022; COVID-19 positive 05/15/2022; fully vaccinated plus booster  Discharge Provider: medical doctor. Primary Care Provider at Discharge: doctor of osteopathic medicine.   Admission Date: 5/15/2022 Discharge Date: 5/19/2022  Condition on discharge: Improving   DETAILS OF HOSPITAL STAY: The patient is a 73 year old man who presented with stroke symptoms of gait instability and slurred speech. He was noted to have some hyponatremia which corrected with normal saline administration. He did have polyuria in response however this also corrected.   CT of head showed no acute intracranial abnormality, just mild atrophy. CT angio of the head and neck showed no acute large vessel occlusion on CTA of the head. Mild atherosclerotic stenosis of the intracranial internal carotid arteries. 40% right carotid bifurcation stenosis.  Moderate degenerative spinal canal stenosis C5-C6. . MRI of brain revealed no acute intracranial abnormality. Volume loss, senescent changes, and tiny remote right temporal occipital and occipital pole cortical infarctions . Neurology thought that he may have drug interaction between Paxlovid and Ranolazine. Paxlovid is potent CYP3A4 inhibitor, and when co-administered with Ranolazine caused CNS side effects of Ranolazine: dizziness, headache, confusion, syncope, ataxia, hypoglycemia, thrombocytopenia, etc. His symptoms nearly resolved by the time of discharge. Because he finished Paxlovid, he would restart Ranolazine at discharge.  Because of tiny remote right temporal occipital and occipital pole cortical infarctions, neurologist recommended echo and to discharge home with ZIO patch x14 days to to evaluate for embolic source of remote stroke.  Echo was fairly unremarkable with EF 50% down from 55% but no clot seen.   Continue ASA 81 mg daily and Pravastatin 40 mg daily   COVID-19 treated with Paxlovid, not requiring oxygen. Vaccinated and boosted with Pfizer. DM type II well controlled, Hgb. A1c 5.9. Continue current meds.  Sinus bradycardia with HR in 60's. Discharged without beta blocker. HTN, BP was initially low, so BP meds Norvasc, metoprolol, Imdur and ramipril were held during this hospitalization. BP was well controlled despite holding above meds. At the time of discharge hewas only restarted on Imdur home dose. Follow up with PCP in 1 week to recheck BP and possible restart some or all BP meds.  Neck pain improved.    PT and OT recommended to discharge home with assist, home PT, shower chair.
Age: 72.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Cerebral infarction, Cervical spinal stenosis, Computerised tomogram head abnormal, Dysarthria, Echocardiogram
Clinical narrative: Hospitalized 05/15/2022-05/19/2022; COVID-19 positive 05/15/2022; fully vaccinated plus booster  Discharge Provider: medical doctor. Primary Care Provider at Discharge: doctor of osteopathic medicine.   Admission Date: 5/15/2022 Discharge Date: 5/19/2022  Condition on discharge: Improving   DETAILS OF HOSPITAL STAY: The patient is a 73 year old man who presented with stroke symptoms of gait instability and slurred speech. He was noted to have some hyponatremia which corrected with normal saline administration. He did have polyuria in response however this also corrected.   CT of head showed no acute intracranial abnormality, just mild atrophy. CT angio of the head and neck showed no acute large vessel occlusion on CTA of the head. Mild atherosclerotic stenosis of the intracranial internal carotid arteries. 40% right carotid bifurcation stenosis.  Moderate degenerative spinal canal stenosis C5-C6. . MRI of brain revealed no acute intracranial abnormality. Volume loss, senescent changes, and tiny remote right temporal occipital and occipital pole cortical infarctions . Neurology thought that he may have drug interaction between Paxlovid and Ranolazine. Paxlovid is potent CYP3A4 inhibitor, and when co-administered with Ranolazine caused CNS side effects of Ranolazine: dizziness, headache, confusion, syncope, ataxia, hypoglycemia, thrombocytopenia, etc. His symptoms nearly resolved by the time of discharge. Because he finished Paxlovid, he would restart Ranolazine at discharge.  Because of tiny remote right temporal occipital and occipital pole cortical infarctions, neurologist recommended echo and to discharge home with ZIO patch x14 days to to evaluate for embolic source of remote stroke.  Echo was fairly unremarkable with EF 50% down from 55% but no clot seen.   Continue ASA 81 mg daily and Pravastatin 40 mg daily   COVID-19 treated with Paxlovid, not requiring oxygen. Vaccinated and boosted with Pfizer. DM type II well controlled, Hgb. A1c 5.9. Continue current meds.  Sinus bradycardia with HR in 60's. Discharged without beta blocker. HTN, BP was initially low, so BP meds Norvasc, metoprolol, Imdur and ramipril were held during this hospitalization. BP was well controlled despite holding above meds. At the time of discharge hewas only restarted on Imdur home dose. Follow up with PCP in 1 week to recheck BP and possible restart some or all BP meds.  Neck pain improved.    PT and OT recommended to discharge home with assist, home PT, shower chair.
Age: 72.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Ejection fraction decreased, Gait disturbance, Glycosylated haemoglobin normal, Hyponatraemia, Hypotension
Clinical narrative: Hospitalized 05/15/2022-05/19/2022; COVID-19 positive 05/15/2022; fully vaccinated plus booster  Discharge Provider: medical doctor. Primary Care Provider at Discharge: doctor of osteopathic medicine.   Admission Date: 5/15/2022 Discharge Date: 5/19/2022  Condition on discharge: Improving   DETAILS OF HOSPITAL STAY: The patient is a 73 year old man who presented with stroke symptoms of gait instability and slurred speech. He was noted to have some hyponatremia which corrected with normal saline administration. He did have polyuria in response however this also corrected.   CT of head showed no acute intracranial abnormality, just mild atrophy. CT angio of the head and neck showed no acute large vessel occlusion on CTA of the head. Mild atherosclerotic stenosis of the intracranial internal carotid arteries. 40% right carotid bifurcation stenosis.  Moderate degenerative spinal canal stenosis C5-C6. . MRI of brain revealed no acute intracranial abnormality. Volume loss, senescent changes, and tiny remote right temporal occipital and occipital pole cortical infarctions . Neurology thought that he may have drug interaction between Paxlovid and Ranolazine. Paxlovid is potent CYP3A4 inhibitor, and when co-administered with Ranolazine caused CNS side effects of Ranolazine: dizziness, headache, confusion, syncope, ataxia, hypoglycemia, thrombocytopenia, etc. His symptoms nearly resolved by the time of discharge. Because he finished Paxlovid, he would restart Ranolazine at discharge.  Because of tiny remote right temporal occipital and occipital pole cortical infarctions, neurologist recommended echo and to discharge home with ZIO patch x14 days to to evaluate for embolic source of remote stroke.  Echo was fairly unremarkable with EF 50% down from 55% but no clot seen.   Continue ASA 81 mg daily and Pravastatin 40 mg daily   COVID-19 treated with Paxlovid, not requiring oxygen. Vaccinated and boosted with Pfizer. DM type II well controlled, Hgb. A1c 5.9. Continue current meds.  Sinus bradycardia with HR in 60's. Discharged without beta blocker. HTN, BP was initially low, so BP meds Norvasc, metoprolol, Imdur and ramipril were held during this hospitalization. BP was well controlled despite holding above meds. At the time of discharge hewas only restarted on Imdur home dose. Follow up with PCP in 1 week to recheck BP and possible restart some or all BP meds.  Neck pain improved.    PT and OT recommended to discharge home with assist, home PT, shower chair.
Age: 72.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Magnetic resonance imaging head normal, Neck pain, Neurological symptom, Polyuria, SARS-CoV-2 test positive
Clinical narrative: Hospitalized 05/15/2022-05/19/2022; COVID-19 positive 05/15/2022; fully vaccinated plus booster  Discharge Provider: medical doctor. Primary Care Provider at Discharge: doctor of osteopathic medicine.   Admission Date: 5/15/2022 Discharge Date: 5/19/2022  Condition on discharge: Improving   DETAILS OF HOSPITAL STAY: The patient is a 73 year old man who presented with stroke symptoms of gait instability and slurred speech. He was noted to have some hyponatremia which corrected with normal saline administration. He did have polyuria in response however this also corrected.   CT of head showed no acute intracranial abnormality, just mild atrophy. CT angio of the head and neck showed no acute large vessel occlusion on CTA of the head. Mild atherosclerotic stenosis of the intracranial internal carotid arteries. 40% right carotid bifurcation stenosis.  Moderate degenerative spinal canal stenosis C5-C6. . MRI of brain revealed no acute intracranial abnormality. Volume loss, senescent changes, and tiny remote right temporal occipital and occipital pole cortical infarctions . Neurology thought that he may have drug interaction between Paxlovid and Ranolazine. Paxlovid is potent CYP3A4 inhibitor, and when co-administered with Ranolazine caused CNS side effects of Ranolazine: dizziness, headache, confusion, syncope, ataxia, hypoglycemia, thrombocytopenia, etc. His symptoms nearly resolved by the time of discharge. Because he finished Paxlovid, he would restart Ranolazine at discharge.  Because of tiny remote right temporal occipital and occipital pole cortical infarctions, neurologist recommended echo and to discharge home with ZIO patch x14 days to to evaluate for embolic source of remote stroke.  Echo was fairly unremarkable with EF 50% down from 55% but no clot seen.   Continue ASA 81 mg daily and Pravastatin 40 mg daily   COVID-19 treated with Paxlovid, not requiring oxygen. Vaccinated and boosted with Pfizer. DM type II well controlled, Hgb. A1c 5.9. Continue current meds.  Sinus bradycardia with HR in 60's. Discharged without beta blocker. HTN, BP was initially low, so BP meds Norvasc, metoprolol, Imdur and ramipril were held during this hospitalization. BP was well controlled despite holding above meds. At the time of discharge hewas only restarted on Imdur home dose. Follow up with PCP in 1 week to recheck BP and possible restart some or all BP meds.  Neck pain improved.    PT and OT recommended to discharge home with assist, home PT, shower chair.
Age: 72.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Sinus bradycardia
Clinical narrative: Hospitalized 05/15/2022-05/19/2022; COVID-19 positive 05/15/2022; fully vaccinated plus booster  Discharge Provider: medical doctor. Primary Care Provider at Discharge: doctor of osteopathic medicine.   Admission Date: 5/15/2022 Discharge Date: 5/19/2022  Condition on discharge: Improving   DETAILS OF HOSPITAL STAY: The patient is a 73 year old man who presented with stroke symptoms of gait instability and slurred speech. He was noted to have some hyponatremia which corrected with normal saline administration. He did have polyuria in response however this also corrected.   CT of head showed no acute intracranial abnormality, just mild atrophy. CT angio of the head and neck showed no acute large vessel occlusion on CTA of the head. Mild atherosclerotic stenosis of the intracranial internal carotid arteries. 40% right carotid bifurcation stenosis.  Moderate degenerative spinal canal stenosis C5-C6. . MRI of brain revealed no acute intracranial abnormality. Volume loss, senescent changes, and tiny remote right temporal occipital and occipital pole cortical infarctions . Neurology thought that he may have drug interaction between Paxlovid and Ranolazine. Paxlovid is potent CYP3A4 inhibitor, and when co-administered with Ranolazine caused CNS side effects of Ranolazine: dizziness, headache, confusion, syncope, ataxia, hypoglycemia, thrombocytopenia, etc. His symptoms nearly resolved by the time of discharge. Because he finished Paxlovid, he would restart Ranolazine at discharge.  Because of tiny remote right temporal occipital and occipital pole cortical infarctions, neurologist recommended echo and to discharge home with ZIO patch x14 days to to evaluate for embolic source of remote stroke.  Echo was fairly unremarkable with EF 50% down from 55% but no clot seen.   Continue ASA 81 mg daily and Pravastatin 40 mg daily   COVID-19 treated with Paxlovid, not requiring oxygen. Vaccinated and boosted with Pfizer. DM type II well controlled, Hgb. A1c 5.9. Continue current meds.  Sinus bradycardia with HR in 60's. Discharged without beta blocker. HTN, BP was initially low, so BP meds Norvasc, metoprolol, Imdur and ramipril were held during this hospitalization. BP was well controlled despite holding above meds. At the time of discharge hewas only restarted on Imdur home dose. Follow up with PCP in 1 week to recheck BP and possible restart some or all BP meds.  Neck pain improved.    PT and OT recommended to discharge home with assist, home PT, shower chair.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Acute kidney injury, Asthenia, Blood test abnormal, COVID-19, Chest X-ray abnormal
Clinical narrative: COVID Vaccine Breakthrough Trough  Pfizer Dose 1 4/8/21 (ER8737) Pfizer Dose 2 4/30/21 (ER8734) COVID Positive 12/1/21  12/6/21: Patient is a 70-year-old female history of chronic COPD, vaccinated against COVID-19 diagnosis with COVID-19 on December 1, 2021 presents to ER with chief complaint of generalized weakness associated with poor p.o. intake, nausea vomiting and diarrhea for the past few days. Evaluations completed the emergency room noted for hypoxia requiring 15 L of high-flow oxygen, chest x-ray demonstrated pneumonia, blood work noted for acute kidney injury, perfusion scan low probability for Regulatory Authority, patient was treated with IV fluid, Decadron, empiric IV antibiotics.  12/15/21: Patient was given steroids, antimicrobials, VTE ppx, O2 supplementation which was weaned down on the day of discharge. She continuously shows signs of improvement towards the day of discharge. Pulmonology was consulted. Patient will require 3L oxygen via nasal cannula with activity. Pt discharged home in stable conditions on a steroid caper course
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Hypophagia, Hypoxia, Nausea, Pneumonia
Clinical narrative: COVID Vaccine Breakthrough Trough  Pfizer Dose 1 4/8/21 (ER8737) Pfizer Dose 2 4/30/21 (ER8734) COVID Positive 12/1/21  12/6/21: Patient is a 70-year-old female history of chronic COPD, vaccinated against COVID-19 diagnosis with COVID-19 on December 1, 2021 presents to ER with chief complaint of generalized weakness associated with poor p.o. intake, nausea vomiting and diarrhea for the past few days. Evaluations completed the emergency room noted for hypoxia requiring 15 L of high-flow oxygen, chest x-ray demonstrated pneumonia, blood work noted for acute kidney injury, perfusion scan low probability for Regulatory Authority, patient was treated with IV fluid, Decadron, empiric IV antibiotics.  12/15/21: Patient was given steroids, antimicrobials, VTE ppx, O2 supplementation which was weaned down on the day of discharge. She continuously shows signs of improvement towards the day of discharge. Pulmonology was consulted. Patient will require 3L oxygen via nasal cannula with activity. Pt discharged home in stable conditions on a steroid caper course
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive, Vaccine breakthrough infection, Ventilation/perfusion scan abnormal, Vomiting
Clinical narrative: COVID Vaccine Breakthrough Trough  Pfizer Dose 1 4/8/21 (ER8737) Pfizer Dose 2 4/30/21 (ER8734) COVID Positive 12/1/21  12/6/21: Patient is a 70-year-old female history of chronic COPD, vaccinated against COVID-19 diagnosis with COVID-19 on December 1, 2021 presents to ER with chief complaint of generalized weakness associated with poor p.o. intake, nausea vomiting and diarrhea for the past few days. Evaluations completed the emergency room noted for hypoxia requiring 15 L of high-flow oxygen, chest x-ray demonstrated pneumonia, blood work noted for acute kidney injury, perfusion scan low probability for Regulatory Authority, patient was treated with IV fluid, Decadron, empiric IV antibiotics.  12/15/21: Patient was given steroids, antimicrobials, VTE ppx, O2 supplementation which was weaned down on the day of discharge. She continuously shows signs of improvement towards the day of discharge. Pulmonology was consulted. Patient will require 3L oxygen via nasal cannula with activity. Pt discharged home in stable conditions on a steroid caper course
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by the state for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Alkalosis, Anaemia, Anticoagulation drug level above therapeutic, Blood gases abnormal
Clinical narrative: COVID Vaccine Breakthrough Case
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Chest X-ray abnormal, Chronic kidney disease, Decreased appetite, Dyspnoea
Clinical narrative: COVID Vaccine Breakthrough Case
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Dyspnoea exertional, Exposure to SARS-CoV-2, Hypoxia, Laboratory test abnormal, Leukocytosis
Clinical narrative: COVID Vaccine Breakthrough Case
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Lung disorder, Malaise, SARS-CoV-2 test positive, Vaccine breakthrough infection, White blood cell count increased
Clinical narrative: COVID Vaccine Breakthrough Case
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Acute kidney injury, Asthenia, COVID-19, Chest X-ray abnormal, Chills
Clinical narrative: COVID VAccine Breakthrough CAse  Pfizer Dose 1 2/19/21 (EN6200) Pfizer Dose 2 3/12/21 (EN6207) COVID Positive 12/8/21  12/13/21: -Patient is an 81 yo male with medical history of HTN, HLD, DMT2, gout , BPH  -He is presenting with worsening COVID symptoms. He tested positive at an outside facility last week wednesday. Symptoms have been ongoing for about a week. Patient is COVID vaccinated. Symptoms include cough, chills, SOB, anorexia, weakness , diarrhoea.  -In the ER vitals significant for fever 101.1, tachycardia 103 , BP 126/67, 92 % on room air  -CXR showed minimal airspace disease at the lung bases, may represent atelectasis or infiltrate from known COVID-19.  -Lab remarkable for lactic acidosis 4, AKI 1.4, Trop <0.01, normal CBC  -He received IV Zosyn and pending IV Vanc  , as well as total 2.8L fluids in the ER for sepsis  12/15/21: Patient is an 81 yo male with medical history of HTN, HLD, DMT2, gout , BPH from home  He presented  with worsening COVID symptoms. He tested positive at an outside facility last week Wednesday.  In the ER vitals significant for fever 101.1, tachycardia 103 , BP 126/67, 92 % on room air  CXR showed minimal airspace disease at the lung bases, may represent atelectasis or infiltrate from known COVID-19.  Lab remarkable for lactic acidosis 4, AKI 1.4, Trop <0.01, normal CBC  He received IV Zosyn and pending IV Vanc  , as well as total 2.8L fluids in the ER for sepsis in ED  He is saturating 93% on room air today.  He will be discharged to home on oral azithromycin and the plan to follow with a PCP  Patient is complaining of fatigue and he will be discharged on VNA for monitoring oxygen, physical therapy and OT.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Cough, Decreased appetite, Diarrhoea, Dyspnoea, Full blood count normal
Clinical narrative: COVID VAccine Breakthrough CAse  Pfizer Dose 1 2/19/21 (EN6200) Pfizer Dose 2 3/12/21 (EN6207) COVID Positive 12/8/21  12/13/21: -Patient is an 81 yo male with medical history of HTN, HLD, DMT2, gout , BPH  -He is presenting with worsening COVID symptoms. He tested positive at an outside facility last week wednesday. Symptoms have been ongoing for about a week. Patient is COVID vaccinated. Symptoms include cough, chills, SOB, anorexia, weakness , diarrhoea.  -In the ER vitals significant for fever 101.1, tachycardia 103 , BP 126/67, 92 % on room air  -CXR showed minimal airspace disease at the lung bases, may represent atelectasis or infiltrate from known COVID-19.  -Lab remarkable for lactic acidosis 4, AKI 1.4, Trop <0.01, normal CBC  -He received IV Zosyn and pending IV Vanc  , as well as total 2.8L fluids in the ER for sepsis  12/15/21: Patient is an 81 yo male with medical history of HTN, HLD, DMT2, gout , BPH from home  He presented  with worsening COVID symptoms. He tested positive at an outside facility last week Wednesday.  In the ER vitals significant for fever 101.1, tachycardia 103 , BP 126/67, 92 % on room air  CXR showed minimal airspace disease at the lung bases, may represent atelectasis or infiltrate from known COVID-19.  Lab remarkable for lactic acidosis 4, AKI 1.4, Trop <0.01, normal CBC  He received IV Zosyn and pending IV Vanc  , as well as total 2.8L fluids in the ER for sepsis in ED  He is saturating 93% on room air today.  He will be discharged to home on oral azithromycin and the plan to follow with a PCP  Patient is complaining of fatigue and he will be discharged on VNA for monitoring oxygen, physical therapy and OT.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Laboratory test abnormal, Lactic acidosis, Lung disorder, Malaise, Pyrexia
Clinical narrative: COVID VAccine Breakthrough CAse  Pfizer Dose 1 2/19/21 (EN6200) Pfizer Dose 2 3/12/21 (EN6207) COVID Positive 12/8/21  12/13/21: -Patient is an 81 yo male with medical history of HTN, HLD, DMT2, gout , BPH  -He is presenting with worsening COVID symptoms. He tested positive at an outside facility last week wednesday. Symptoms have been ongoing for about a week. Patient is COVID vaccinated. Symptoms include cough, chills, SOB, anorexia, weakness , diarrhoea.  -In the ER vitals significant for fever 101.1, tachycardia 103 , BP 126/67, 92 % on room air  -CXR showed minimal airspace disease at the lung bases, may represent atelectasis or infiltrate from known COVID-19.  -Lab remarkable for lactic acidosis 4, AKI 1.4, Trop <0.01, normal CBC  -He received IV Zosyn and pending IV Vanc  , as well as total 2.8L fluids in the ER for sepsis  12/15/21: Patient is an 81 yo male with medical history of HTN, HLD, DMT2, gout , BPH from home  He presented  with worsening COVID symptoms. He tested positive at an outside facility last week Wednesday.  In the ER vitals significant for fever 101.1, tachycardia 103 , BP 126/67, 92 % on room air  CXR showed minimal airspace disease at the lung bases, may represent atelectasis or infiltrate from known COVID-19.  Lab remarkable for lactic acidosis 4, AKI 1.4, Trop <0.01, normal CBC  He received IV Zosyn and pending IV Vanc  , as well as total 2.8L fluids in the ER for sepsis in ED  He is saturating 93% on room air today.  He will be discharged to home on oral azithromycin and the plan to follow with a PCP  Patient is complaining of fatigue and he will be discharged on VNA for monitoring oxygen, physical therapy and OT.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive, Sepsis, Tachycardia, Troponin, Vaccine breakthrough infection
Clinical narrative: COVID VAccine Breakthrough CAse  Pfizer Dose 1 2/19/21 (EN6200) Pfizer Dose 2 3/12/21 (EN6207) COVID Positive 12/8/21  12/13/21: -Patient is an 81 yo male with medical history of HTN, HLD, DMT2, gout , BPH  -He is presenting with worsening COVID symptoms. He tested positive at an outside facility last week wednesday. Symptoms have been ongoing for about a week. Patient is COVID vaccinated. Symptoms include cough, chills, SOB, anorexia, weakness , diarrhoea.  -In the ER vitals significant for fever 101.1, tachycardia 103 , BP 126/67, 92 % on room air  -CXR showed minimal airspace disease at the lung bases, may represent atelectasis or infiltrate from known COVID-19.  -Lab remarkable for lactic acidosis 4, AKI 1.4, Trop <0.01, normal CBC  -He received IV Zosyn and pending IV Vanc  , as well as total 2.8L fluids in the ER for sepsis  12/15/21: Patient is an 81 yo male with medical history of HTN, HLD, DMT2, gout , BPH from home  He presented  with worsening COVID symptoms. He tested positive at an outside facility last week Wednesday.  In the ER vitals significant for fever 101.1, tachycardia 103 , BP 126/67, 92 % on room air  CXR showed minimal airspace disease at the lung bases, may represent atelectasis or infiltrate from known COVID-19.  Lab remarkable for lactic acidosis 4, AKI 1.4, Trop <0.01, normal CBC  He received IV Zosyn and pending IV Vanc  , as well as total 2.8L fluids in the ER for sepsis in ED  He is saturating 93% on room air today.  He will be discharged to home on oral azithromycin and the plan to follow with a PCP  Patient is complaining of fatigue and he will be discharged on VNA for monitoring oxygen, physical therapy and OT.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Asthenia, Blood albumin decreased, Blood iron increased, Blood test abnormal
Clinical narrative: 05/11/2022 My Crohn's disease had been doing okay. I started feeling extreme fatigue and was weak. The next day I worked from home because I still did not feel well. I took off on Friday because I was so weak, fatigued, had cramping in my legs, diarrhea. I could not function and slept all weekend. I returned to work that on Monday. I did okay at work until Wednesday and I had another episode of extreme fatigue. This persisted through the weekend. Then I began having stomach cramping and pain, especially upper right abdomen. I could not eat for 3 days. I had loud noises from my stomach. I had an excruciating headache and diarrhea. I laid around in bed for the better part of the day. I had tele health with my GI doctor on May 12 and had blood work done which revealed an iron deficiency and my iron was really high. On May 16 I went to my PCP. She ordered an iron infusion which I had on May 17. The nurse and doctor sent me to an urgent care. They admitted me into the hospital after spending the night in urgent care on 5/18/2022 and discharged on 5/19/2022. They ran more tests, and my albumin was low. At the hospital I received Solumedrol and liquids through an IV. I was diagnosed with Noro virus and was in a Crohn's flair up. I turned around pretty quickly and started feeling better. I am supposed to set up an appointment with my doctor. My stomach is settled where I can actually eat again.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: C-reactive protein increased, Condition aggravated, Crohn's disease, Diarrhoea, Fatigue
Clinical narrative: 05/11/2022 My Crohn's disease had been doing okay. I started feeling extreme fatigue and was weak. The next day I worked from home because I still did not feel well. I took off on Friday because I was so weak, fatigued, had cramping in my legs, diarrhea. I could not function and slept all weekend. I returned to work that on Monday. I did okay at work until Wednesday and I had another episode of extreme fatigue. This persisted through the weekend. Then I began having stomach cramping and pain, especially upper right abdomen. I could not eat for 3 days. I had loud noises from my stomach. I had an excruciating headache and diarrhea. I laid around in bed for the better part of the day. I had tele health with my GI doctor on May 12 and had blood work done which revealed an iron deficiency and my iron was really high. On May 16 I went to my PCP. She ordered an iron infusion which I had on May 17. The nurse and doctor sent me to an urgent care. They admitted me into the hospital after spending the night in urgent care on 5/18/2022 and discharged on 5/19/2022. They ran more tests, and my albumin was low. At the hospital I received Solumedrol and liquids through an IV. I was diagnosed with Noro virus and was in a Crohn's flair up. I turned around pretty quickly and started feeling better. I am supposed to set up an appointment with my doctor. My stomach is settled where I can actually eat again.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Feeding disorder, Gastrointestinal sounds abnormal, Headache, Impaired work ability, Infusion
Clinical narrative: 05/11/2022 My Crohn's disease had been doing okay. I started feeling extreme fatigue and was weak. The next day I worked from home because I still did not feel well. I took off on Friday because I was so weak, fatigued, had cramping in my legs, diarrhea. I could not function and slept all weekend. I returned to work that on Monday. I did okay at work until Wednesday and I had another episode of extreme fatigue. This persisted through the weekend. Then I began having stomach cramping and pain, especially upper right abdomen. I could not eat for 3 days. I had loud noises from my stomach. I had an excruciating headache and diarrhea. I laid around in bed for the better part of the day. I had tele health with my GI doctor on May 12 and had blood work done which revealed an iron deficiency and my iron was really high. On May 16 I went to my PCP. She ordered an iron infusion which I had on May 17. The nurse and doctor sent me to an urgent care. They admitted me into the hospital after spending the night in urgent care on 5/18/2022 and discharged on 5/19/2022. They ran more tests, and my albumin was low. At the hospital I received Solumedrol and liquids through an IV. I was diagnosed with Noro virus and was in a Crohn's flair up. I turned around pretty quickly and started feeling better. I am supposed to set up an appointment with my doctor. My stomach is settled where I can actually eat again.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Iron deficiency, Malaise, Muscle spasms, Norovirus infection, Red blood cell sedimentation rate increased
Clinical narrative: 05/11/2022 My Crohn's disease had been doing okay. I started feeling extreme fatigue and was weak. The next day I worked from home because I still did not feel well. I took off on Friday because I was so weak, fatigued, had cramping in my legs, diarrhea. I could not function and slept all weekend. I returned to work that on Monday. I did okay at work until Wednesday and I had another episode of extreme fatigue. This persisted through the weekend. Then I began having stomach cramping and pain, especially upper right abdomen. I could not eat for 3 days. I had loud noises from my stomach. I had an excruciating headache and diarrhea. I laid around in bed for the better part of the day. I had tele health with my GI doctor on May 12 and had blood work done which revealed an iron deficiency and my iron was really high. On May 16 I went to my PCP. She ordered an iron infusion which I had on May 17. The nurse and doctor sent me to an urgent care. They admitted me into the hospital after spending the night in urgent care on 5/18/2022 and discharged on 5/19/2022. They ran more tests, and my albumin was low. At the hospital I received Solumedrol and liquids through an IV. I was diagnosed with Noro virus and was in a Crohn's flair up. I turned around pretty quickly and started feeling better. I am supposed to set up an appointment with my doctor. My stomach is settled where I can actually eat again.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Back pain, Blood glucose normal, Blood urea increased, COVID-19
Clinical narrative: COVID Vaccine Breakthrough Case Pfizer Dose 1 3/12/21 (EN6205) Pfizer Dose 2 4/2/21 (EP7533) COVID Positive 12/3/21  12/3/21: Patient is a 71-year-old female with a past medical history significant for hypertension, hyperlipidemia, OSA, type 2 diabetes, CAD s/p CABG, pacemaker, history of CVA, chronic back pain.  The patient presents to the ED today with complaints of significant weakness.  The patient states over the last few weeks she has been significantly weak, completely losing her ability to ambulate as of yesterday.  The patient's accompanying symptoms include fever, chills, flank pain.  She states her accompanying symptoms began yesterday.  The patient denies any nausea, vomiting, chest pain or shortness of breath. She rates her flank pain 10/10 and describes it as stabbing despite receiving IV pain medications for management.  The patient is vaccinated against COVID-19.  The patient does have known chronic back pain with sciatica to her right leg.  She states however her lower back/flank pain is different from her chronic pain.  The patient denies any tobacco use, illicit drug abuse or alcohol abuse.     Of note, the patient was admitted to the facility on 10/26/2021 discharged on 11/03/2021 the patient was admitted due to confusion and to rule out stroke.  The patient was discharged to a rehabilitation facility for deconditioning.  The patient was discharged from rehabilitation facility on 11/11/2021 with PT/OT in her home.  The patient states she has been progressively weakening ever since then.  The patient admits to having 1 fall since being discharged from the rehab facility.   Upon arrival to ED patient's heart rate 61, respirations 16, pulse ox 97% on room air, blood pressure 130/64. Lumbar spine x-ray reveals severe degenerative changes in the lumbar spine including degenerative disc disease and facet arthropathy; the appearance of the spinous process would be compatible with Bastrop syndrome, degenerative listhesis in the lumbar spine.  Pelvic x-ray reveals no acute fractures. Patient's laboratory findings are significant for glucose 134, BUN 31, hemoglobin 10.1, hematocrit 34.4.  The patient received 1 Lortab, 2 mg IV morphine, 4 mg IV morphine, 750 mg IV Levaquin in ED.  12/13/21: 71-year-old woman who presented worsening generalized weakness, inability to ambulate.  Labs were suggestive of urinary tract infection, COVID-19 PCR was positive and renal function shows signs of dehydration.  She was admitted to the hospitalist service, IV rehydration was initiated, empiric antibiotic therapy for treatment of urinary tract infection was started with urine cultures subsequently yielding Klebsiella pneumoniae.  She was also found to be significantly physically deconditioned and recommended for skilled placement on discharge.  She remained stable from a respiratory perspective anti diabetic criteria for treatment of COVID-19 pneumonia throughout hospital course.  She has been accepted to rehab and his been discharged today in stable medical condition to continue rehabilitation.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19 pneumonia, Chills, Confusional state, Culture urine positive, Dehydration
Clinical narrative: COVID Vaccine Breakthrough Case Pfizer Dose 1 3/12/21 (EN6205) Pfizer Dose 2 4/2/21 (EP7533) COVID Positive 12/3/21  12/3/21: Patient is a 71-year-old female with a past medical history significant for hypertension, hyperlipidemia, OSA, type 2 diabetes, CAD s/p CABG, pacemaker, history of CVA, chronic back pain.  The patient presents to the ED today with complaints of significant weakness.  The patient states over the last few weeks she has been significantly weak, completely losing her ability to ambulate as of yesterday.  The patient's accompanying symptoms include fever, chills, flank pain.  She states her accompanying symptoms began yesterday.  The patient denies any nausea, vomiting, chest pain or shortness of breath. She rates her flank pain 10/10 and describes it as stabbing despite receiving IV pain medications for management.  The patient is vaccinated against COVID-19.  The patient does have known chronic back pain with sciatica to her right leg.  She states however her lower back/flank pain is different from her chronic pain.  The patient denies any tobacco use, illicit drug abuse or alcohol abuse.     Of note, the patient was admitted to the facility on 10/26/2021 discharged on 11/03/2021 the patient was admitted due to confusion and to rule out stroke.  The patient was discharged to a rehabilitation facility for deconditioning.  The patient was discharged from rehabilitation facility on 11/11/2021 with PT/OT in her home.  The patient states she has been progressively weakening ever since then.  The patient admits to having 1 fall since being discharged from the rehab facility.   Upon arrival to ED patient's heart rate 61, respirations 16, pulse ox 97% on room air, blood pressure 130/64. Lumbar spine x-ray reveals severe degenerative changes in the lumbar spine including degenerative disc disease and facet arthropathy; the appearance of the spinous process would be compatible with Bastrop syndrome, degenerative listhesis in the lumbar spine.  Pelvic x-ray reveals no acute fractures. Patient's laboratory findings are significant for glucose 134, BUN 31, hemoglobin 10.1, hematocrit 34.4.  The patient received 1 Lortab, 2 mg IV morphine, 4 mg IV morphine, 750 mg IV Levaquin in ED.  12/13/21: 71-year-old woman who presented worsening generalized weakness, inability to ambulate.  Labs were suggestive of urinary tract infection, COVID-19 PCR was positive and renal function shows signs of dehydration.  She was admitted to the hospitalist service, IV rehydration was initiated, empiric antibiotic therapy for treatment of urinary tract infection was started with urine cultures subsequently yielding Klebsiella pneumoniae.  She was also found to be significantly physically deconditioned and recommended for skilled placement on discharge.  She remained stable from a respiratory perspective anti diabetic criteria for treatment of COVID-19 pneumonia throughout hospital course.  She has been accepted to rehab and his been discharged today in stable medical condition to continue rehabilitation.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Facet joint syndrome, Fall, Flank pain, Gait inability, Haematocrit decreased
Clinical narrative: COVID Vaccine Breakthrough Case Pfizer Dose 1 3/12/21 (EN6205) Pfizer Dose 2 4/2/21 (EP7533) COVID Positive 12/3/21  12/3/21: Patient is a 71-year-old female with a past medical history significant for hypertension, hyperlipidemia, OSA, type 2 diabetes, CAD s/p CABG, pacemaker, history of CVA, chronic back pain.  The patient presents to the ED today with complaints of significant weakness.  The patient states over the last few weeks she has been significantly weak, completely losing her ability to ambulate as of yesterday.  The patient's accompanying symptoms include fever, chills, flank pain.  She states her accompanying symptoms began yesterday.  The patient denies any nausea, vomiting, chest pain or shortness of breath. She rates her flank pain 10/10 and describes it as stabbing despite receiving IV pain medications for management.  The patient is vaccinated against COVID-19.  The patient does have known chronic back pain with sciatica to her right leg.  She states however her lower back/flank pain is different from her chronic pain.  The patient denies any tobacco use, illicit drug abuse or alcohol abuse.     Of note, the patient was admitted to the facility on 10/26/2021 discharged on 11/03/2021 the patient was admitted due to confusion and to rule out stroke.  The patient was discharged to a rehabilitation facility for deconditioning.  The patient was discharged from rehabilitation facility on 11/11/2021 with PT/OT in her home.  The patient states she has been progressively weakening ever since then.  The patient admits to having 1 fall since being discharged from the rehab facility.   Upon arrival to ED patient's heart rate 61, respirations 16, pulse ox 97% on room air, blood pressure 130/64. Lumbar spine x-ray reveals severe degenerative changes in the lumbar spine including degenerative disc disease and facet arthropathy; the appearance of the spinous process would be compatible with Bastrop syndrome, degenerative listhesis in the lumbar spine.  Pelvic x-ray reveals no acute fractures. Patient's laboratory findings are significant for glucose 134, BUN 31, hemoglobin 10.1, hematocrit 34.4.  The patient received 1 Lortab, 2 mg IV morphine, 4 mg IV morphine, 750 mg IV Levaquin in ED.  12/13/21: 71-year-old woman who presented worsening generalized weakness, inability to ambulate.  Labs were suggestive of urinary tract infection, COVID-19 PCR was positive and renal function shows signs of dehydration.  She was admitted to the hospitalist service, IV rehydration was initiated, empiric antibiotic therapy for treatment of urinary tract infection was started with urine cultures subsequently yielding Klebsiella pneumoniae.  She was also found to be significantly physically deconditioned and recommended for skilled placement on discharge.  She remained stable from a respiratory perspective anti diabetic criteria for treatment of COVID-19 pneumonia throughout hospital course.  She has been accepted to rehab and his been discharged today in stable medical condition to continue rehabilitation.